Clinical Trial Update: 24-Week Study to Assess the PD, Safety, Tolerability, and PK of GLM101 in Participants With PMM2-CDG [Phase 2]

View source ↗

Summary

A Phase 2 24-week trial evaluating GLM101 in PMM2-CDG has completed, reporting on pharmacodynamics, safety, tolerability, and pharmacokinetics.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Phosphomannomutase Deficiency

Drugs mentioned

• GLM101 (GLM101)

Snippet

Sponsor: Glycomine, Inc. | Conditions: Pmm2-CDG, Phosphomannomutase 2 Deficiency | Phase 2 | Status: COMPLETED